Bill Grogan
Analyst · Wells Fargo. Please go ahead
Thanks, Andy. I will start with our consolidated financial results. I am on Slide 4. Order rates slowed down in Q4. We were up 1% overall and 2% organically. For the year, orders were up 7% overall and 6% organically, a solid year from an order intake perspective. For the Q4 slowdown, I will get into more detail as we go through the segment discussions, but I would like to say this, our core industrial franchises did extremely well in the quarter. Secondly, we did see some timing related issues where we had some early receipts in Q3 and some delays out of Q4. And finally, we did see some true softness in a few markets, but we think the quarter is closer to 5% organic growth number if we normalize for some of these items closer to where we think our new run-rate will be for 2019. From a sales perspective, Q4 revenue was up 5% overall and organically as well. While fiscal year revenue was up 9% overall and 8% organically, this was our highest organic sales growth since 2011. We expanded gross margins by 10 basis points for both Q4 and the year primarily due to production efficiencies and volume leverage. This was partially offset by investments we made in engineering related to new product development. Q4 adjusted operating margin was 23.3%, up 120 basis points and fiscal year adjusted op margin was 23.4%, a 150 basis point increase. The teams did an excellent job of leveraging the great organic performance throughout the year in the bottom line results. Q4 net income was $98 million, resulting in EPS of $1.27. Excluding restructuring expenses, adjusted EPS was $1.31, up $0.19 or 17%. Full year net income was $411 million with EPS of $5.29. Again, excluding restructuring expenses, adjusted EPS was $5.41, up $1.10 or 26% higher than last year. Our Q4 effective tax rate was 23.8%, resulting in an ETR of 22.4% for the year. Both rates were lower than our previous guidance resulting in $0.04 of EPS favorability in the quarter. The difference was primarily due to additional interpretations the IRS provided in tax reform, along with the reduction in the statutory rate in the Netherlands. Free cash flow for Q4 was strong at $137 million, up 14% and 136% of adjusted net income, which resulted in full year free cash flow of $423 million, which was up 9% and 101% of adjusted net income. Free cash flow was only up 9% for the year, primarily due to working capital and capital expenditures investments that we made to support our long-term growth. In regards to the balance sheet, it remains very healthy. Gross debt leverage is 1.3x, while our net debt leverage is at 0.6x. The combination of our strong balance sheet, capacity on the revolver and free cash flow provides us the ability to deploy well over $1.5 billion over the next 12 months. I will now turn to our segment discussion I am on Slide 5 starting with Fluid & Metering. FMT continues to deliver strong numbers from both an order and a revenue perspective. Q4 orders were flat overall, up 2% organically, while full year orders were up 6% overall and 7% organically. The lower order rate was primarily driven by the timing of precision orders for Banjo, wherein Q3 orders were up 36% and Q4 orders were down 5% as well as we saw some project push out in the quarter in the chemical and energy markets. Q4 sales were up 7% overall and 8% organically, while full year sales were up 8% overall and 9% organically. Adjusted for restructuring expenses, Q4 op margin was 29.1%, up 70 basis points over the prior year quarter. Full year op margin was 29.2%, up 150 basis points. FMT’s performance was primarily driven by market growth across the industrial and chemical sectors, coupled with continued stability in the muni market. Those served as the core drivers of growth or year as evidenced by strong global demand in core distribution and project wins across the group. Oil price fluctuations in Q4 did postpone some investments, but we are seeing market conditions improve as we have seen prices increase and stabilize. Ag order rates did slow in Q4 primarily due to the timing of the pre-season orders I mentioned earlier, but the fundamental economics in ags do give us some concern heading into 2019. Project funnels in various end-markets remains strong and active, but have been less predictable in timing as we close out the year with the backdrop of caution in the global market. However, overall, the targeted growth efforts across our businesses in this segment continue to gain wins and market share regardless of the slower market support. Let’s move on to Health & Science, turning to Slide 6. We are very pleased with the Health & Science results both for Q4 as well as the fiscal year. Q4 orders were up 10% overall and 9% organically, while full year orders were up 10% overall and 7% organically. In the quarter, the 9% organic growth was aided by some timing shifts related to receipts of annual POs by some of our large OEM customers. Q4 sales were up 8% overall and 7% organically, while fiscal year sales were up 9% and 6% organically. Excluding restructuring expenses, Q4 adjusted op margin was 23.4% and full year adjusted op margin was 23.6%, both margins up over 110 basis points over the prior year. HST’s performance was primarily driven by continued success in our IVD/BIO and our Life Science Optics businesses, where they continue to outpace the market due to targeted MPT efforts in collaboration with key customers. HST industrial remains strong with double-digit growth due to some large wins within our gas business and also continued strength in their day rate distribution business. Strong execution in MPT drove customer lead times and helped enable growth. We also had some solid project wins in the pharma and food space that drove double-digit orders increases. Finally, despite the downturn in the semicon market, our Sealing Solutions continue to perform well in oil and gas and the industrial end markets. I am moving on to our final segment, Diversified. I am on Slide 7. Q4 orders were down 10% overall and 8% organically primarily due to the lumpiness of our dispensing business, coupled with the timing of large annual blanket order at BAND-IT, while full year orders were up 5% overall and up 4% organically. Q4 sales were down 2% overall and 1% organically, while full year sales were up 9% overall and 7% organically. I will give more details on that in a moment. Excluding restructuring expenses, Q4 adjusted op margin of 26.5% was flat with the prior year, while adjusted fiscal year end operated margin was 26.8%, up 170 basis points from prior year. FSD sales performance was primarily driven by our fire business reporting high single-digit growth due to strength across most of their product categories and geographies. Rescue sales were up due to strong project volume in emerging markets and several wins in key markets in the U.S. BAND-IT saw growth across most of its verticals with transportation sales up due to significant volume increases in their airbag applications through new platform wins. They also had some nice project wins in the Middle East. The sales growth in Fire & Rescue and in BAND-IT was muted by the lumpiness of the dispensing business, which was down 25% for the quarter, but it was up 7% for the year. Dispensing does have market leading positions across all of their geographies, but it is our most project oriented business and creates tough comps from time-to-time. The dispensing sales decrease was the primary reason for op margin being down – being flat for the quarter as well for FSD. I will now pass it back to Andy to talk about our expectations for 2019.